Amphastar is transitioning from a legacy generic model to a branded specialty portfolio, anchored by the Baqsimi acquisition, which has stabilized revenue growth at 5.4% YoY in 2026Q2 despite ongoing generic pricing pressure. Gross margin recovery to 50.8% in ...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.91+46.8% vs $0.62 | $184M+2.2% vs $180M |
Q2 2026 May 7, 2026 | $0.42-40.0% vs $0.70 | $171M-1.3% vs $173M |
Q1 2026 Feb 26, 2026 | $0.73-19.2% vs $0.90 | $183M-3.0% vs $189M |
Q4 2025 Nov 6, 2025 | $0.93+20.8% vs $0.77 | $192M+0.7% vs $190M |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Amphastar
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) has been given a consensus recommendation of "Reduce" by the eight analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average twelve-month price target among
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total value of $239,400.00. Following the completion of the transaction, the executive vice president owned 169,203
Benchmark AMPH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Amphastar Pharmaceuticals, Inc. (AMPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.14 | $1.11B | 12.38 | -1.65% | 13.63% | 12.9% | — | |
| $99.80 | $6.5B | 29.27 | 0.5% | 17.69% | 23.27% | — | |
| $36.42 | $1.43B | 227.63 | 3.63% | 1.96% | 2.13% | — | |
| $15.96 | $2.21B | -1.55 | -2.75% | -41.85% | -55.97% | — | |
| $54.65 | $4.38B | -14.57 | — | — | -30.58% | — | |
| $40.70 | $2.36B | -59.85 | 8.63% | -13.23% | -10.42% | — |
Amphastar Pharmaceuticals, Inc. (AMPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Amphastar Pharmaceuticals, Inc. (AMPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 13, 2026·SEC
Jul 8, 2026·SEC
Get notified when AMPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amphastar Pharmaceuticals, Inc. (AMPH) stock FAQ — growth, dividends, profitability & financials explained
Amphastar Pharmaceuticals, Inc. (AMPH) reported $730.0M in revenue for fiscal year 2025. This represents a 257% increase from $204.3M in 2012.
Amphastar Pharmaceuticals, Inc. (AMPH) saw revenue decline by 1.7% over the past year.
Yes, Amphastar Pharmaceuticals, Inc. (AMPH) is profitable, generating $78.5M in net income for fiscal year 2025 (13.6% net margin).
Amphastar Pharmaceuticals, Inc. (AMPH) has a return on equity (ROE) of 12.9%. This is reasonable for most industries.
Amphastar Pharmaceuticals, Inc. (AMPH) generated $152.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
